Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial
Debra International, the Department of Dermatology, Medical Center-University of Freiburg (Berta-Ottenstein Advanced Clinician Scientist Program of the Medical Faculty), and the German Research Foundation.
Authors
- Dedee Frances Murrell (ORCID: https://orcid.org/0000-0003-2971-0199)
- Agnes Schwieger‐Briel (ORCID: https://orcid.org/0000-0001-7679-3981)
- Tobias Zahn (ORCID: https://orcid.org/0000-0002-1306-1879)
- Franziska Schauer (ORCID: https://orcid.org/0000-0001-5147-0123)
- Katja Reineker
- Brigitte Stiller (ORCID: https://orcid.org/0000-0002-7657-4647)
- Stella Gewert (ORCID: https://orcid.org/0000-0002-7165-0938)
- Hagen Ott
- Alexander Nyström (ORCID: https://orcid.org/0000-0002-4666-2240)
- Dimitra Kiritsi (ORCID: https://orcid.org/0000-0002-2331-8981)
- Claudia Schmoor (ORCID: https://orcid.org/0000-0001-5610-9425)
- Antonia Reimer‐Taschenbrecker (ORCID: https://orcid.org/0000-0002-3378-4476)
- Olga Grishina
- Leena Bruckner–Tuderman
Institutions
- University of Freiburg (DE)
- Aristotle University of Thessaloniki (GR)
- University Medical Center Freiburg (DE)
- Kinderkrankenhaus auf der Bult (DE)
- St George Hospital (AU)
- University Children's Hospital Zurich (CH)
- Universitäts-Herzzentrum Freiburg-Bad Krozingen (DE)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2024-10-31
- DOI
- https://doi.org/10.1016/j.eclinm.2024.102900
- Citations
- 9
- Primary Topic
- Skin and Cellular Biology Research
- Type
- article
- Field-Weighted Citation Impact
- 2.93
Funders
- Deutsche Forschungsgemeinschaft
- Albert-Ludwigs-Universität Freiburg
- Debra International
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz
- Medizinische Fakultät der Albert-Ludwigs-Universität Freiburg